Sign in

CIK 0001590877 · Non-accelerated filer<br>Smaller reporting company

REGENXBIO Inc.

Sign in to watch
Ticker
RGNX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
operating
EIN
471851754
Phone
240-552-8181
Business address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
Former names
ReGenX Biosciences, LLC
  1. 4 Grant or award Chief Technology Officer acquired 27,777 shares (grant or award)
  2. 4 Grant or award Chief Strategy & Legal Officer acquired 34,722 shares (grant or award)
  3. 4 Grant or award Chief Medical Officer acquired 34,722 shares (grant or award)
  4. 4 Grant or award Chief Financial Officer acquired 24,305 shares (grant or award)
  5. 4 Shares withheld for taxes Chief Technology Officer gave up 234 shares (to pay taxes)
  6. 4 Shares withheld for taxes Chief Financial Officer gave up 4,902 shares (to pay taxes)
  7. 4 Open-market buy Director bought 102,603 shares at an average $9.25 ($949,381)
  8. 3 Insider Initial Statement of Ownership
  9. 4 Shares withheld for taxes Chief Medical Officer gave up 7,468 shares (to pay taxes)
  10. 4 Shares withheld for taxes Chief Strategy & Legal Officer gave up 4,699 shares (to pay taxes)
  11. 4 Shares withheld for taxes Chief Executive Officer gave up 6,818 shares (to pay taxes)
  12. 4 Planned sale Chief Medical Officer sold 2,161 shares at $13.64 ($29,476)
  13. 4 Open-market sale Chief Medical Officer sold 56,333 shares at an average $12.23 ($688,756)
  14. 4 Grant or award Director acquired 9,807 shares (grant or award)
  15. 4 Grant or award Director acquired 9,807 shares (grant or award)
  16. 4 Grant or award Director acquired 9,807 shares (grant or award)
  17. 4 Grant or award Director acquired 9,807 shares (grant or award)
  18. 4 Grant or award Director acquired 9,807 shares (grant or award)
  19. 4 Grant or award Director acquired 9,807 shares (grant or award)
  20. 4 Grant or award Director acquired 9,807 shares (grant or award)

Page 1 of 22 · 435 filings